Tweetovi

Blokirali ste korisnika/cu @BiotechBeau

Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @BiotechBeau

  1. 31. sij

    New restaurant in Back Bay opens with theme of oncology markets

    Poništi
  2. proslijedio/la je Tweet
    29. sij

    Now GPCR PROTACs! Another gene family susceptible to UbP mediated degradation.

    Poništi
  3. proslijedio/la je Tweet
    23. sij

    Deerfield, one of the largest healthcare focused hedge funds, is betting BIG on both gene tx & the Philadelphia cluster. The venture will help with housing & relocation for experts who join, per release. They are calling it THE COLONY, a name JG Ballard would be proud of.

    Poništi
  4. proslijedio/la je Tweet
    21. sij

    Sad to see such ignorance from a govt official. - does not make money. $1.7b in accum losses - HemA is not patent protected and has cost $700m to dev - Patients spend days wkly in treatment centers and $500k annually for ERT Gene therapy is a solution for budget not issue

    Poništi
  5. proslijedio/la je Tweet
    14. sij

    Great POC study on this new complimentary approach to PROTAC. Heterobifunctional Molecules Induce Dephosphorylation of Kinases–A Proof of Concept Study -

    Poništi
  6. proslijedio/la je Tweet
    9. sij

    Oh man, cancers are just too damn smart... Why KRAS(G12C) inhibitors result in only partial responses w/ rather short durability? "Rapid non-uniform adaptation to conformation-specific KRAS(G12C) inhibition"

    Poništi
  7. proslijedio/la je Tweet
    8. sij

    Protein degradation space gaining more interest: gets an ok from the FTC for a significant research collaboration with Nurix, reports this will be highlighted at

    Prikaži ovu nit
    Poništi
  8. proslijedio/la je Tweet

    This Media Post will serve as a reminder that war powers reside in the Congress under the United States Constitution. And that you should read the War Powers Act. And that you’re not a dictator.

    Prikaži ovu nit
    Poništi
  9. proslijedio/la je Tweet
    4. sij

    A few thoughts on the S-1 after digging through. I'm a big believer in rebuilding the care delivery stack, with an eye toward care continuity and the patient experience, but I think it's fair to say I started and finished my perusal with a mixed read on ONEM. 1/n

    Prikaži ovu nit
    Poništi
  10. proslijedio/la je Tweet
    3. sij

    "Of all the antibiotics approved in the last 10 years, only 2 will have an annual revenue over $100 million in 2019." Rolf Wagenaar via

    Prikaži ovu nit
    Poništi
  11. proslijedio/la je Tweet
    1. sij

    Excessive alcohol consumption associated with AFib. Patients with paroxysmal or persistent AFib who were in sinus rhythm and who were consuming 10 or more drinks per week were randomly assigned to either alcohol abstinence or continued drinking for 6 mos.

    Poništi
  12. proslijedio/la je Tweet

    A vaccine developed to treat tuberculosis, now also used to treat bladder cancer, was found to be associated with a 4x reduction in Alzheimer’s disease.

    Poništi
  13. proslijedio/la je Tweet

    Cool paper. Could really improve ability to purify cell populations of interest in manufacturing of cell therapies. Example: Could capture CD3 T cells with aptamer, then add oligo antidote to seamlessly release. Very useful for the cell therapy field.

    Prikaži ovu nit
    Poništi
  14. proslijedio/la je Tweet
    23. pro 2019.

    PROTAC-Mediated Degradation of KRAS Protein for Anticancer Therapeutics

    Poništi
  15. proslijedio/la je Tweet
    15. srp 2019.

    Let’s play a little game. Let’s say that you’re the CSO at a cancer pharma company, and you have to choose a target to go after. Here’s a gene – high expression is associated with poor prognosis in brain cancer. Looks like a good candidate for an inhibitor right?

    Prikaži ovu nit
    Poništi
  16. proslijedio/la je Tweet

    I bet the owner tried for years to share it, but no one ever replied to his emails...

    Poništi
  17. proslijedio/la je Tweet

    Would you pay $1 million for an unproven, untested anti-aging gene therapy?

    Poništi
  18. proslijedio/la je Tweet
    13. pro 2019.

    Wow. Extraordinary graphic of proportion of drug revenues by disease area over time. Main story is about Cancer, but note early DAA era (Infection) and shift to INSTI-Rx (HIV) -- big advances with big prices. h/t

    Poništi
  19. proslijedio/la je Tweet

    Oncology companies continued to attract the lion’s share of IPO dollars in 2019, with more than $2.5 billion raised - find out more about trends in 2019 IPOs in this analysis by

    Poništi
  20. proslijedio/la je Tweet
    7. pro 2019.

    Many recent papers about , but this may be the most noteworthy one: Increasing tolerability for Bcl-XL targeting with a VHL-based degrader by boosting anti-tumor efficacy while sparing platelets (due to low expression of VHL) (1/2)

    Prikaži ovu nit
    Poništi

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.

    Možda bi vam se svidjelo i ovo:

    ·